DANIEL ERNESTO
CASTELLANO GAUNA
Profesor asociado
University of Antwerp
Amberes, BélgicaUniversity of Antwerp-ko ikertzaileekin lankidetzan egindako argitalpenak (6)
2023
-
EV-301 long-term outcomes: 24-month findings from the phase III trial of enfortumab vedotin versus chemotherapy in patients with previously treated advanced urothelial carcinoma
Annals of Oncology
-
Publisher Correction: Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial (Nature Medicine, (2019), 25, 11, (1706-1714), 10.1038/s41591-019-0628-7)
Nature Medicine
2022
-
Final Results of Neoadjuvant Atezolizumab in Cisplatin-ineligible Patients with Muscle-invasive Urothelial Cancer of the Bladder
European Urology, Vol. 82, Núm. 2, pp. 212-222
2021
-
Enfortumab vedotin in previously treated advanced urothelial carcinoma
New England Journal of Medicine, Vol. 384, Núm. 12, pp. 1125-1135
2019
-
Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial
Nature Medicine, Vol. 25, Núm. 11, pp. 1706-1714